We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca plc. (AZN - Free Report) announced results from an outcomes study, which showed that its blockbuster type II diabetes drug Farxiga can reduce some cardiovascular risks. The DECLARE- TIMI 58 study met the primary efficacy endpoint with Farxiga, a SGLT2 inhibitor, demonstrating non-inferiority of major adverse cardiovascular events (MACE) over placebo.
The phase III cardiovascular outcomes study was carried out in more than 17,000 patients from 33 countries with type-II diabetes who have multiple CV risk factors or established CV disease. The study compared the effect of Farxiga versus placebo in reducing the risk of MACE in such patients.
MACE is a composite endpoint of CV death, non-fatal myocardial infarction or non-fatal stroke. Data from the study showed that Farxiga led to a statistical significant reduction in hospitalization for heart failure or CV death in such patients, thereby meeting one of the two primary efficacy endpoints. Meanwhile, for the other endpoint, though fewer CV events were observed in the Farxiga arm, this did not reach statistical significance.
Detailed data from the study will be presented at the annual session of the American Heart Association to be held in November.
AstraZeneca’s shares have gained 8.6% so far this year, outperforming an increase of 7.1% for the industry.
Farxiga recorded sales of $639 million in the first half of 2018, up 36% as the medicine continued to lead the market in terms of volume.
With death from cardiovascular diseases being significantly higher in adults with diabetes compared to those without diabetes, the addition of positive cardiovascular (CV) outcomes on labels of diabetes drugs can give sales a shot in the arm.
If the cardiovascular data from the DECLARE-TIMI 58 study is approved to be included in the label of the drug, Farxiga can cater to a broad range of patients - those with type-II diabetes and at cardiovascular risk. This can further boost sales of the drug.
Other SGLT2 inhibitors available in the market are J&J’s (JNJ - Free Report) Invokana and Eli Lilly’s (LLY - Free Report) Jardiance. The label of Jardiance already includes CV risk reduction data from the EMPA-REG OUTCOME study. However, for Invokana, in July, the FDA delayed its decision on J&J’s regulatory application looking for approval to include the cardiovascular indication on the label of Invokana. The FDA is now expected to give its decision in October.
Bristol-Myers’ earnings estimates increased 3.4% for 2018 and 2.7% for 2019 over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 6.39%. Shares of the company have risen 13.9% in the past three months.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk
AstraZeneca plc. (AZN - Free Report) announced results from an outcomes study, which showed that its blockbuster type II diabetes drug Farxiga can reduce some cardiovascular risks. The DECLARE- TIMI 58 study met the primary efficacy endpoint with Farxiga, a SGLT2 inhibitor, demonstrating non-inferiority of major adverse cardiovascular events (MACE) over placebo.
The phase III cardiovascular outcomes study was carried out in more than 17,000 patients from 33 countries with type-II diabetes who have multiple CV risk factors or established CV disease. The study compared the effect of Farxiga versus placebo in reducing the risk of MACE in such patients.
MACE is a composite endpoint of CV death, non-fatal myocardial infarction or non-fatal stroke. Data from the study showed that Farxiga led to a statistical significant reduction in hospitalization for heart failure or CV death in such patients, thereby meeting one of the two primary efficacy endpoints. Meanwhile, for the other endpoint, though fewer CV events were observed in the Farxiga arm, this did not reach statistical significance.
Detailed data from the study will be presented at the annual session of the American Heart Association to be held in November.
AstraZeneca’s shares have gained 8.6% so far this year, outperforming an increase of 7.1% for the industry.
Farxiga recorded sales of $639 million in the first half of 2018, up 36% as the medicine continued to lead the market in terms of volume.
With death from cardiovascular diseases being significantly higher in adults with diabetes compared to those without diabetes, the addition of positive cardiovascular (CV) outcomes on labels of diabetes drugs can give sales a shot in the arm.
If the cardiovascular data from the DECLARE-TIMI 58 study is approved to be included in the label of the drug, Farxiga can cater to a broad range of patients - those with type-II diabetes and at cardiovascular risk. This can further boost sales of the drug.
Other SGLT2 inhibitors available in the market are J&J’s (JNJ - Free Report) Invokana and Eli Lilly’s (LLY - Free Report) Jardiance. The label of Jardiance already includes CV risk reduction data from the EMPA-REG OUTCOME study. However, for Invokana, in July, the FDA delayed its decision on J&J’s regulatory application looking for approval to include the cardiovascular indication on the label of Invokana. The FDA is now expected to give its decision in October.
AstraZeneca currently carries a Zacks Rank #3 (Hold). A better-ranked large-cap drug stocks is Bristol-Myers Squibb Company (BMY - Free Report) which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Bristol-Myers’ earnings estimates increased 3.4% for 2018 and 2.7% for 2019 over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 6.39%. Shares of the company have risen 13.9% in the past three months.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>